AVYCAZ (Ceftazidime and Avibactam) Patent
This MDL consolidates two related Hatch-Waxman patent actions brought by the branded manufacturer of AVYCAZ, an antibacterial medicine indicated for serious bacterial infections, against a generic drug company that filed an abbreviated new drug application to market a generic version ahead of patent expiration. Centralized in the District of New Jersey in 2025, the docket brings together actions originally filed in the District of New Jersey and the Northern District of Illinois against the same defendant over the same asserted patents, and now carries 1 pending action.
What this docket illustrates is the JPML's ordinary function operating at a small scale: rather than allowing the same generic manufacturer to litigate identical patent-validity and infringement questions in two separate districts, the Panel consolidated the two actions for coordinated pretrial proceedings, avoiding duplicated discovery and inconsistent claim-construction rulings on the same patent claims. Resolution timing here follows the standard Hatch-Waxman pattern: patent validity and infringement questions are litigated on a schedule that runs alongside, but does not strictly control, the generic manufacturer's separate FDA approval timeline for the product.
For anyone studying how the JPML applies its consolidation authority even to small, two-action pharmaceutical patent disputes, this docket is a useful minimal example: consolidation serves a case-management purpose independent of docket size, and even a small Hatch-Waxman MDL follows the same basic resolution structure, claim construction, validity, and infringement, as a much larger multi-defendant pharmaceutical patent fight. Criterica Intelligence's platform tracks this consolidation logic across every active MDL regardless of size.
The branded manufacturer of the antibacterial medicine AVYCAZ alleges that a generic drug company's abbreviated new drug application, seeking approval to market a generic version, infringes its patents on the product.
The same generic manufacturer filed or faced related patent litigation over the same product's patents in two different federal districts, and the JPML consolidated those two actions rather than allowing them to proceed separately.
Patent validity and infringement determinations proceed on their own litigation schedule that runs alongside, rather than strictly controlling, the generic manufacturer's separate FDA regulatory approval timeline for the product.
That consolidation serves a case-management function independent of the number of actions involved; even a two-action dispute is centralized when it would otherwise duplicate discovery and litigation of identical patent questions in separate courts.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.